Impact of rivaroxaban on stent thrombosis and secondary prevention of | RRCC
ATLAS ACS2-TIMI 51 – TIMI STUDY GROUP
ATLAS ACS2-TIMI 51 – TIMI STUDY GROUP
Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial) - ScienceDirect
![PDF] The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis](https://d3i71xaburhd42.cloudfront.net/32d1dd0e96918f7d38cc1a05cb6a983573e968e5/15-Table1-1.png "PDF] The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis")
PDF] The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis
Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction: Results From the ATLAS ACS-2–TIMI-51 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary
ATLAS ACS 2-TIMI 51: Safety Endpoints - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
![PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/28cdc9f7ebf4529018a7c9ea31d2282fb44f4c13/3-Table1-1.png "PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar")
PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar
PDF) The "dual-pathway" strategy after acute coronary syndrome: Rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial
ATLAS ACS-TIMI 46 – TIMI STUDY GROUP
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome | NEJM
Results of the ATLAS ACS-TIMI 46 Study Published in The Lancet - wikidoc
ATLAS ACS 2-TIMI 51: Treatment-emergent Fatal Bleeds and Intracerebral Bleeds - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
Xarelto® Global:
Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51 - ScienceDirect
ATLAS ACS-2 TIMI 51: Stent thrombosis in Patients with Acute Coronary Syndromes treated with Rivaroxaban | tctmd.com
![PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/28cdc9f7ebf4529018a7c9ea31d2282fb44f4c13/4-Figure1-1.png "PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar")
PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar
ATLAS ACS 2-TIMI 51: Primary Efficacy Endpoint CV Death / MI / Stroke - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
PDF) The "dual-pathway" strategy after acute coronary syndrome: Rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial
Frontiers | Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis
The “Dual‐Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2‐TIMI 51 Trial - Cohen - 2014 - Cardiovascular Therapeutics - Wiley Online Library
The “Dual‐Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2‐TIMI 51 Trial - Cohen - 2014 - Cardiovascular Therapeutics - Wiley Online Library
![PDF] The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis](https://d3i71xaburhd42.cloudfront.net/32d1dd0e96918f7d38cc1a05cb6a983573e968e5/16-Table2-1.png "PDF] The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis")
PDF] The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis
ATLAS ACS 2-TIMI 51 - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
